Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Technology appraisal guidance
Reference number: TA329
Published: 25 February 2015

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: final appraisal determination document

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: final appraisal determination document

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: final appraisal determination document
12 December 2014
(582.19 Kb 49 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 10 December 2014